Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 13/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372866 | 0.92 | GAA (0.52) | CHEK2NPY5RGAAGRIN1GRIN2B | |
| SCHEMBL19058671 | 0.88 | HDAC6 (0.62) | GRIN1GRIN2B | |
| SCHEMBL5732767 | 0.83 | CHEK2 (0.59) | CHEK2NPY5RGAA | |
| SCHEMBL5377680 | 0.83 | CYP2C9 (0.45) | GAAGRIN1GRIN2B | |
| SCHEMBL5377683 | 0.83 | CYP2C9 (0.45) | GAAGRIN1GRIN2B | |
| SCHEMBL5733660 | 0.81 | GAA (0.54) | CHEK2GAAGRIN1GRIN2B | |
| SCHEMBL4436265 | 0.81 | GRIN2B (0.65) | GRIN1GRIN2B | |
| SCHEMBL5374164 | 0.81 | MEN1 (0.55) | — | |
| SCHEMBL5374168 | 0.81 | MEN1 (0.55) | — | |
| SCHEMBL6001989 | 0.79 | GFER (0.62) | NPY5RGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | claimed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | claimed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1080078-B1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | disclosed |
| EP-1080078-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999061426-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | CHEK2 4577/4885NPY5R 181/4885GAA 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.